Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350,000 Compounds

被引:55
作者
Baell, Jonathan B. [1 ,2 ,3 ]
机构
[1] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
[2] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
ORGANIC SMALL MOLECULES; HIGH-THROUGHPUT; DRUG DISCOVERY; CHEMICAL SPACE; REACTIVE COMPOUNDS; FALSE POSITIVES; VINYL SULFONES; DIVERSITY; LIBRARIES; DESIGN;
D O I
10.1021/ci300461a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In establishing what we propose is the globe's highest quality collection of available screening compounds, it is convincingly shown that the globe's pool of such compounds is extremely shallow and can be represented by fewer than 350,000 compounds. To support our argument, we discuss and fully disclose our extensive battery of functional group filters. We discuss the use of PAINS filters and also show the effect of similarity exclusion on structure-activity relationships. We show why limited analogue representation requires screening at higher concentrations to capture hit classes for difficult targets that otherwise may be prosecuted unsuccessfully. We construct our arguments in a structurally focused manner to be most useful to medicinal chemists, the key players in drug discovery.
引用
收藏
页码:39 / 55
页数:17
相关论文
共 63 条
[1]   Cheminformatics approaches to analyze diversity in compound screening libraries [J].
Akella, Lakshmi B. ;
DeCaprio, David .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (03) :325-330
[2]   Epigenetic protein families: a new frontier for drug discovery [J].
Arrowsmith, Cheryl H. ;
Bountra, Chas ;
Fish, Paul V. ;
Lee, Kevin ;
Schapira, Matthieu .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (05) :384-400
[3]   NIH Molecular Libraries Initiative [J].
Austin, CP ;
Brady, LS ;
Insel, TR ;
Collins, FS .
SCIENCE, 2004, 306 (5699) :1138-1139
[4]   Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase [J].
Babaoglu, Kerim ;
Simeonov, Anton ;
Lrwin, John J. ;
Nelson, Michael E. ;
Feng, Brian ;
Thomas, Craig J. ;
Cancian, Laura ;
Costi, M. Paola ;
Maltby, David A. ;
Jadhav, Ajit ;
Inglese, James ;
Austin, Christopher P. ;
Shoichet, Brian K. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (08) :2502-2511
[5]   Redox-active nuisance screening compounds and their classification [J].
Baell, Jonathan B. .
DRUG DISCOVERY TODAY, 2011, 16 (17-18) :840-841
[6]   Observations on screening-based research and some concerning trends in the literature [J].
Baell, Jonathan B. .
FUTURE MEDICINAL CHEMISTRY, 2010, 2 (10) :1529-1546
[7]   New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays [J].
Baell, Jonathan B. ;
Holloway, Georgina A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) :2719-2740
[8]   Therapeutic potential of boron-containing compounds [J].
Baker, Stephen J. ;
Ding, Charles Z. ;
Akama, Tsutomu ;
Zhang, Yong-Kang ;
Hernandez, Vincent ;
Xia, Yi .
FUTURE MEDICINAL CHEMISTRY, 2009, 1 (07) :1275-1288
[9]   On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53 [J].
Bista, Michal ;
Smithson, David ;
Pecak, Aleksandra ;
Salinas, Gabriella ;
Pustelny, Katarzyna ;
Min, Jaeki ;
Pirog, Artur ;
Finch, Kristin ;
Zdzalik, Michal ;
Waddell, Brett ;
Wladyka, Benedykt ;
Kedracka-Krok, Sylwia ;
Dyer, Michael A. ;
Dubin, Grzegorz ;
Guy, R. Kiplin .
PLOS ONE, 2012, 7 (06)
[10]  
Bohacek RS, 1996, MED RES REV, V16, P3, DOI 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO